Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal

被引:10
作者
Cooper, Brian C.
Sites, Cynthia K.
Casson, Peter R.
Toth, Michael J.
机构
[1] Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA
[2] Univ Vermont, Dept Med, Burlington, VT 05405 USA
关键词
ovarian hormones; estrogen; insulin sensitivity; GnRH agonist;
D O I
10.1016/j.fertnstert.2006.11.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Aging is associated with reduced tissue sensitivity to insulin. In women, these age-related changes may be accelerated by menopause. The effect of ovarian hormone deficiency on tissue insulin sensitivity in humans, however, has not been defined clearly. Thus, the goal of this study was to evaluate the effect of suppression of endogenous ovarian hormone production on insulin-stimulated glucose disposal. Design: Randomized, single-blind, placebo-controlled trial. Setting: General clinical research center. Patients: Thirteen healthy, nonobese premenopausal women. Intervention(s): Insulin-stimulated glucose disposal was determined by hyperinsulinemic (40 mU/m(2)/min) clamp during the early to midfollicular and midluteal phase of the menstrual cycle. Volunteers then received 2 months of treatment with the GnRH agonist (GnRHa) leuprolide acetate (n = 6) or placebo (n = 7) and were retested. Main Outcome Measure(s): Total, oxidative, and nonoxidative insulin-stimulated glucose disposal. Result(s): Because no effect of cycle phase was found on total, oxidative, or nonoxidative glucose disposal, pretreatment follicular and luteal phase values were averaged. Treatment with GnRHa had no effect on total glucose disposal (GnRHa: 1.0.6 +/- 0.9 to 10.8 +/- 0.9 vs. placebo: 10.2 +/- 0.7 to 10.4 +/- 1.0 mg/kg fat-free mass/min, P = .99). Similarly, there was no effect of GnRHa administration on oxidative (GnRHa: 2.77 +/- 0.58 to 3.89 +/- 0.58 vs. placebo: 2.74 +/- 0.42 to 3.33 +/- 0.62 mg/kg fat-free mass/min, P = .52; n = 6 and 6, respectively) or nonoxidative (GnRHa: 7.82 +/- 0.68 to 6.91 +/- 0.66 vs. placebo: 7.94 +/- 0.72 to 7.79 +/- 0.99 mg/kg fat-free mass/min, P = .59; n = 6 and 6, respectively) components of glucose disposal. Conclusion(s): Our results suggest that endogenous ovarian hormones do not regulate tissue responsiveness to insulin or intracellular pathways of glucose disposal.
引用
收藏
页码:1131 / 1138
页数:8
相关论文
共 50 条
  • [21] Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy
    Warnock, JK
    Bundren, JC
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (02) : 311 - 316
  • [22] Successful use of gonadotropin-releasing hormone agonist in a patient with pulmonary endometriosis
    Koizumi, T
    Inagaki, H
    Takabayashi, Y
    Kubo, K
    RESPIRATION, 1999, 66 (06) : 544 - 546
  • [23] Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
    Finch, Ann R.
    Caunt, Christopher J.
    Armstrong, Stephen P.
    McArdle, Craig A.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2009, 297 (03): : C591 - C600
  • [24] Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma
    Higashijima, T
    Kataoka, A
    Nishida, T
    Yakushiji, M
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996, 68 (1-2): : 169 - 173
  • [25] Fertility Preservation by Endocrine Suppression of Ovarian Function Using Gonadotropin-Releasing Hormone Agonists: The End of the Controversy?
    Blumenfeld, Zeev
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1895 - +
  • [26] Efficacy of induced luteinizing hormone surge after "trigger" with gonadotropin-releasing hormone agonist
    Shapiro, Bruce S.
    Daneshmand, Said T.
    Restrepo, Humberto
    Garner, Forest C.
    Aguirre, Martha
    Hudson, Cynthia
    FERTILITY AND STERILITY, 2011, 95 (02) : 826 - 828
  • [27] OVARIAN SUPPRESSION WITH THE GONADOTROPIN-RELEASING-HORMONE AGONIST GOSERELIN (ZOLADEX) IN MANAGEMENT OF THE PREMENSTRUAL TENSION SYNDROME
    WEST, CP
    HILLIER, H
    HUMAN REPRODUCTION, 1994, 9 (06) : 1058 - 1063
  • [28] Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin
    Thomsen, Lise
    Humaidan, Peter
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2015, 27 (03) : 210 - 214
  • [29] Gonadotropin-releasing hormone agonist treatment reduced serum interleukin-6 concentrations in patients with ovarian endometriomas
    Iwabe, T
    Harada, T
    Sakamoto, Y
    Iba, Y
    Horie, S
    Mitsunari, M
    Terakawa, N
    FERTILITY AND STERILITY, 2003, 80 (02) : 300 - 304
  • [30] Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all'' strategy: a prospective multicentric study
    Griesinger, Georg
    Schultz, Laura
    Bauer, Thomas
    Broessner, Anke
    Frambach, Thorsten
    Kissler, Stefan
    FERTILITY AND STERILITY, 2011, 95 (06) : 2029 - U195